The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
|Slideshows|December 12, 2017
Top Hematologic Cancer News of 2017
Author(s)Cancer Network Editors
In this slide show we highlight some of the top news on hematologic cancers in 2017, including effective therapies for pediatric hematologic malignancies, a variety of FDA approvals, new discoveries in myeloma, and more.
Advertisement
Advertisement
Related to this article
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
5